Effect of Rifampin on Steady-State Pharmacokinetics of Atazanavir with Ritonavir in Healthy Volunteers

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Antimicrobial Agents and Chemotherapy

• Publication date

  2006-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1128/AAC.00461-06PMID 17005814PMCID PMC1610067
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Atazanavir

  2012cited by this paper
• ATAZANAVIR: EFFECTS ON P-GLYCOPROTEIN TRANSPORT AND CYP3A METABOLISM IN VITRO

  2005cited by this paper
• Simplifying the treatment of HIV infection with ritonavir-boosted protease inhibitors in antiretroviral-experienced patients.

  2005cited by this paper
• Therapeutic Drug Monitoring and Drug–Drug Interactions Involving Antiretroviral Drugs

  2005cited by this paper
• Pharmacokinetic Enhancement of Protease Inhibitor Therapy

  2004influential reference
• Pharmacokinetics of Adjusted-Dose Lopinavir-Ritonavir Combined with Rifampin in Healthy Volunteers

  2004cited by this paper
• Induction of CYP3A4 by Efavirenz in Primary Human Hepatocytes: Comparison With Rifampin and Phenobarbital

  2004cited by this paper
• Atazanavir: a new protease inhibitor to treat HIV infection.

  2004cited by this paper
• Ritonavir-Enhanced Pharmacokinetics of Nelfinavir/M8 during Rifampin Use

  2003cited by this paper
• The growing burden of tuberculosis: global trends and interactions with the HIV epidemic.

  2003cited by this paper
• Comparative Pharmacokinetics and Pharmacodynamics of the Rifamycin Antibacterials

  2001influential reference
• Treatment of tuberculosis in HIV-infected patients: safety and antiretroviral efficacy of the concomitant use of ritonavir and rifampin.

  2001cited by this paper
• Principles and practice of HIV‐protease inhibitor pharmacoenhancement

  2001influential reference
• Effect of indinavir on the pharmacokinetics of rifampicin in HIV‐infected patients *

  2001cited by this paper
• The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin.

  1999cited by this paper
• Ritonavir enables combined therapy with rifampin and saquinavir.

  1999cited by this paper

• Quantitative prediction of drug-drug interactions arising from CYP3A4 induction using chimeric mice with humanized liver

  2025cites this paper
• Intracellular Penetration of Atazanavir, Ritonavir and Dolutegravir With Concomitant Rifampicin: A Dose Escalation Study

  2025cites this paper
• Hepatic OATP1B zonal distribution: Implications for rifampicin‐mediated drug–drug interactions explored within a PBPK framework

  2024cites this paper
• HIV/Tuberculosis Coinfection in Pregnancy and the Postpartum Period

  2023cites this paper
• Pharmacokinetics and Safety of Twice-daily Ritonavir-boosted Atazanavir With Rifampicin

  2023cites this paper
• A literature review of liver function test elevations in rifampin drug–drug interaction studies

  2022cites this paper
• Safety and Pharmacokinetics of Double-Dose Lopinavir/Ritonavir + Rifampin vs. Lopinavir/Ritonavir + Daily Rifabutin for Treatment of HIV-TB Coinfection.

  2021cites this paper
• Adoption of evidence-informed guidelines in prescribing protease inhibitors for HIV-Tuberculosis co-infected patients on rifampicin and effects on HIV treatment outcomes in Uganda

  2021cites this paper
• Impact of CYP2B6 genotype, tuberculosis therapy, and formulation on efavirenz pharmacokinetics in infants and children under 40 months of age

  2021cites this paper
• Investigating the Utility of Humanized Pregnane X Receptor-Constitutive Androstane Receptor-CYP3A4/7 Mouse Model to Assess CYP3A-Mediated Induction

  2021cites this paper
• Predicting Drug–Drug Interactions between Rifampicin and Ritonavir-Boosted Atazanavir Using PBPK Modelling

  2021cites this paper
• The crosstalk between antiretrovirals pharmacology and HIV drug resistance

  2020cites this paper
• Prioritisation of potential anti-SARS-CoV-2 drug repurposing opportunities based on ability to achieve adequate target site concentrations derived from their established human pharmacokinetics

  2020cites this paper
• Prioritization of Anti‐SARS‐Cov‐2 Drug Repurposing Opportunities Based on Plasma and Target Site Concentrations Derived from their Established Human Pharmacokinetics

  2020cites this paper
• Predictors of failure on second-line antiretroviral therapy with protease inhibitor mutations in Uganda

  2020cites this paper
• Pharmacokinetics of antiretroviral and tuberculosis drugs in children with HIV/TB co-infection: a systematic review

  2020cites this paper
• Drug‐drug interaction of atazanavir on UGT1A1‐mediated glucuronidation of molidustat in human

  2020cites this paper
• Co-treatment of Tuberculosis and HIV: Pharmacologic Considerations

  2019cites this paper
• A Comprehensive Framework for Physiologically‐Based Pharmacokinetic Modeling in Matlab

  2019cites this paper
• HIV and Tuberculosis: A Formidable Alliance

  2019cites this paper
• Tuberculosis-HIV treatment with rifampicin or rifabutin: are the outcomes different?

  2019cites this paper
• The Effect of Rifampin on the Pharmacokinetics and Safety of Lorlatinib: Results of a Phase One, Open-Label, Crossover Study in Healthy Participants

  2019cites this paper
• Predictors of switch to and early outcomes on third-line antiretroviral therapy at a large public-sector clinic in Johannesburg, South Africa

  2018cites this paper
• Virological Outcomes of Second-line Protease Inhibitor–Based Treatment for Human Immunodeficiency Virus Type 1 in a High-Prevalence Rural South African Setting: A Competing-Risks Prospective Cohort Analysis

  2017cites this paper
• Safety and Efficacy of Atazanavir Powder and Ritonavir in HIV-1-Infected Infants and Children From 3 Months to <11 Years of Age: The PRINCE-2 Study

  2017cites this paper
• Coadministration of Rifampin Significantly Reduces Odanacatib Concentrations in Healthy Subjects

  2017cites this paper
• Interaction of Rifampin and Darunavir-Ritonavir or Darunavir-Cobicistat In Vitro

  2017cites this paper
• Efecto de las concentraciones de ritonavir en la farmacocinética de atazanavir: aplicación de técnicas de modelado y simulación farmacocinético poblacional /

  2016cites this paper
• Drug Interactions with Cobicistat- or Ritonavir-Boosted Elvitegravir.

  2016cites this paper
• Integrated therapy for HIV and tuberculosis

  2016cites this paper
• Effect of Itraconazole and Rifampin on the Pharmacokinetics of Olaparib in Patients With Advanced Solid Tumors: Results of Two Phase I Open-label Studies.

  2016cites this paper
• Getting to 90-90-90 in paediatric HIV: What is needed?

  2015cites this paper
• Pharmacological Interactions Between Rifampicin and Antiretroviral Drugs: Challenges and Research Priorities for Resource-Limited Settings

  2015cites this paper
• The role of therapeutic drug monitoring and pharmacogenetic testing in the management of HIV infection: a review.

  2015cites this paper
• Drugs used in tuberculosis and leprosy

  2014cites this paper
• Treatment Optimization in Patients Co-Infected with HIV and Mycobacterium tuberculosis Infections: Focus on Drug–Drug Interactions with Rifamycins

  2014cites this paper
• Updated Guidelines on Managing Drug Interactions in the Treatment of HIV-Related Tuberculosis

  2014cites this paper
• Clinical pharmacological studies in tuberculosis patients: ‘Research from the Kilimanjaro Region,Tanzania’

  2014cites this paper
• The effect of tuberculosis treatment at the time of combination antiretroviral therapy (cART) initiation on response to cART among HIV-infected individuals

  2013cites this paper
• Frecuencia y factores asociados a daño hepático inducido por medicamentos en tratamiento antituberculosis

  2013cites this paper
• Protease inhibitor-containing antiretroviral treatment and tuberculosis: can rifabutin fill the breach?

  2012cites this paper
• Coadministration of Lopinavir/Ritonavir and Rifampicin in HIV and Tuberculosis Co-Infected Adults in South Africa

  2012cites this paper
• TB and HIV Therapeutics: Pharmacology Research Priorities

  2012cites this paper
• Pharmacokinetics and 48 Week Efficacy of Adjusted Dose Indinavir/Ritonavir in Rifampicin-Treated HIV/Tuberculosis-Coinfected Patients: A Pilot Study

  2012cites this paper
• Management of tuberculosis in HIV-infected patients.

  2012cites this paper
• HIV-infected adolescents: relationship between atazanavir plasma levels and bilirubin concentrations.

  2011cites this paper
• Initiating antiretrovirals during tuberculosis treatment: a drug safety review

  2011cites this paper
• Pharmacokinetic Drug Interactions of Antimicrobial Drugs: A Systematic Review on Oxazolidinones, Rifamycines, Macrolides, Fluoroquinolones, and Beta-Lactams

  2011cites this paper
• Tuberculosis Associated with HIV Infection

  2011cites this paper
• AtriplaR/anti-TB combination in TB/HIV patients. Drug in focus

  2011cites this paper
• Population pharmacokinetics of atazanavir/ritonavir in HIV-1-infected children and adolescents.

  2011cites this paper
• British HIV Association guidelines for the treatment of TB / HIV coinfection 2010

  2011cites this paper
• [Clinical relevance of drug interactions].

  2011cites this paper
• British HIV Association guidelines for the treatment of TB/HIV coinfection 2011

  2011cites this paper
• Antiretroviral Therapy Outcomes in HIV-Infected Children after Adjusting Protease Inhibitor Dosing during Tuberculosis Treatment

  2011cites this paper
• Rifamycin Use in HIV-Infected Patients with Tuberculosis

  2011cites this paper
• Antiretroviral Therapy Responses Among Children Attending a Large Public Clinic in Soweto, South Africa

  2011cites this paper
• Clinical Pharmacokinetic and Pharmacodynamic Profile of the HIV Integrase Inhibitor Elvitegravir

  2011cites this paper
• Running title: Management of HIV-1-TB

  2010cites this paper
• Modeling the TB/HIV-1 Co-Infection and the Effects of Its Treatment

  2010cites this paper
• Clinical pharmacology and pharmacokinetics of antiretrovirals in Asia

  2010cites this paper
• Initial response to protease-inhibitor-based antiretroviral therapy among children less than 2 years of age in South Africa: effect of cotreatment for tuberculosis.

  2010cites this paper
• Clinical management of tuberculosis and HIV-1 co-infection

  2010cites this paper
• Antiretroviral therapy for HIV-associated tuberculosis

  2009cites this paper
• Clinical pharmacology, efficacy and safety of atazanavir: a review

  2009cites this paper
• Hepatotoxicity and Gastrointestinal Intolerance When Healthy Volunteers Taking Rifampin Add Twice-Daily Atazanavir and Ritonavir

  2009cites this paper
• A Low Dose of Ritonavir‐Boosted Atazanavir Provides Adequate Pharmacokinetic Parameters in HIV‐1‐Infected Thai Adults

  2009cites this paper
• Clinicalpharmacology,efficacy andsafetyofatazanavir:areview

  2009cites this paper
• Atazanavir/ritonavir: a review of its use in HIV therapy.

  2008cites this paper
• Differences in the pharmacokinetics of protease inhibitors between healthy volunteers and HIV-infected persons

  2008cites this paper
• [Pharmacology, pharmacokinetic features and interactions of atazanavir].

  2008cites this paper
• Antiretroviral therapy in developing countries: pharmacologic considerations

  2008cites this paper
• Treatment of HIV‐related tuberculosis—unresolved issues

  2008cites this paper
• Drug interactions involving combination antiretroviral therapy and other anti-infective agents: repercussions for resource-limited countries.

  2008cites this paper
• Protease inhibitor plasma concentrations in HIV antiretroviral therapy.

  2008cites this paper
• Pharmacokinetic Considerations for Selection of HAART in Treatment-Naive HIV-Infected Individuals, 2008: More Than it Seems?

  2008cites this paper
• The Effect of Atazanavir and Atazanavir/Ritonavir on UDP‐Glucuronosyltransferase Using Lamotrigine as a Phenotypic Probe

  2008cites this paper
• Farmacología, aspectos farmacocinéticos e interacciones de atazanavir

  2008cites this paper
• High incidence of adverse events in healthy volunteers receiving rifampicin and adjusted doses of lopinavir/ritonavir tablets

  2008cites this paper
• Pharmacokinetic interaction between rifampicin and ritonavir‐boosted atazanavir in HIV‐infected patients *

  2007cites this paper
• [Approach to evaluating the clinical relevance of drug interactions in HIV-infected patients].

  2007cites this paper
• Concurrent drug therapy for tuberculosis and HIV infection in resource-limited settings: present status and future prospects

  2007cites this paper
• Effect of Concomitantly Administered Rifampin on the Pharmacokinetics and Safety of Atazanavir Administered Twice Daily

  2007cites this paper
• Pharmacokinetic interaction between rifampicin and the once-daily combination of saquinavir and low-dose ritonavir in HIV-infected patients with tuberculosis.

  2007cites this paper
• Interacciones medicamentosas en pacientes infectados con el VIH: aproximación para establecer y evaluar su relevancia clínica

  2007cites this paper
• Tuberculosis in sub-Saharan Africa: opportunities, challenges, and change in the era of antiretroviral treatment.

  2006cites this paper
• Drug–drug interactions and tolerance in combining antituberculosis and antiretroviral therapy

  2005cites this paper